7,376.86

+23.13

+0.31%

51,285.73

-237.33

-0.46%

24,579.42

+264.43

+1.09%

2,754.11

+24.22

+0.89%

4.8590

+0.0220

+0.45%

25.64

-2.54

-9.01%

4,074.90

-38.60

-0.94%

75,919.86

+340.26

+0.45%

Crude Oil Dec 26

90.34

-0.18

-0.20%

US Private Equity

10,772.76

+11.83

+0.11%

OTC Markets OTCQB - Delayed Quote USD

Bioxytran, Inc. (BIXT)

0.0230 +0.0002 (+0.88%)

At close: November 5 at 4:00:00 PM EST

Loading Chart for BIXT

Chart Range Bar

Interval:

In partnership with ChartIQ

Bioxytran Secures Attested Free Sale Certification for A-SUQAR®, Opening the Path to the UAE and Gulf Markets

Bioxytran Secures Attested Free Sale Certification for A-SUQAR®, Opening the Path to the UAE and Gulf Markets

Bioxytran Completes Production of Two Dietary Supplements: V-LO® for Immune Health and A-SUQAR® for Healthy Blood Sugar

Bioxytran Completes Production of Two Dietary Supplements: V-LO® for Immune Health and A-SUQAR® for Healthy Blood Sugar

Bioxytran Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID, a Novel Galectin Antagonist Designed with Artificial Intelligence

Bioxytran Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID, a Novel Galectin Antagonist Designed with Artificial Intelligence

Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25

Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25

BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT

BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT

Bioxytran Leverages Artificial Super Intelligence (ASI) to Design Broad-Spectrum Antiviral and Anti-Cancer Metastasis Drugs

Bioxytran Leverages Artificial Super Intelligence (ASI) to Design Broad-Spectrum Antiviral and Anti-Cancer Metastasis Drugs

Bioxytran Announces Publication of Corporate Research Report by Globe Small Cap Research

Bioxytran Announces Publication of Corporate Research Report by Globe Small Cap Research

Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M

Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M

Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19

Presenting on Emerging Growth Conference 88 Day 2 on December 11; Register to live stream

Presenting on Emerging Growth Conference 88 Day 2 on December 11; Register to live stream

Mobilize your Website

View Site in Mobile | Classic

Share by: